Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron

Generic drugmaker Lupin has settled with Astellas Pharma a patent infringement quality relating to overactive bladder cause Mirabegron.

The institution and its wholly owned U.S. subsidiary Lupin Pharmaceuticals Inc. person entered into a colony and licence statement with Astellas resolving the pending litigation and allowing Lupin to proceed to merchantability Mirabegron.

Under the presumption of the agreement, Lupin volition wage Astellas $90 million, which includes a prepaid enactment outgo of $75 million, and a prepaid per portion licence interest for each portion of Lupin merchandise sold from the day of the colony done September 2027. The colony presumption are confidential, Lupin said successful a filing connected Tuesday (February 10, 2026).

Lupin had successful April 2024 launched Mirabegron Extended-Release Tablets, 25 mg, a generic equivalent of Astellas Pharma Global Development Inc.’s Myrbetriq Extended-Release Tablets, 25 mg, successful the U.S. pursuing support from the U.S. Food and Drug Administration (U.S. FDA). Citing past existent manufacture income numbers, it had had past said Mirabegron Extended-Release Tablets, 25 mg had estimated yearly income of $1,019 cardinal successful the U.S.

Astellas Pharma had filed a patent infringement lawsuit against Lupin. The United States District Court for the District of Delaware successful April 2025 had ruled successful favour of Astellas Pharma regarding the validity of its U.S. patent and said the issues of whether Lupin’s products infringe the patent, damages, and immoderate further invalidity theories volition beryllium litigated astatine a consolidated assemblage proceedings successful 2026.